Mommox (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mommox, is a corticosteroid presented as a nasal spray for nasal use. It treats allergic rhinitis, including seasonal allergic rhinitis, by reducing inflammation of the nasal mucosa and relieving symptoms such as congestion, itching and sneezing. Mommox is marketed in the European Union and complies with relevant quality standards for nasal corticosteroid therapy.

GNH USA supplies Mommox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mommox (mometasone furoate) is a topical corticosteroid used to manage inflammatory conditions of the nasal passages.

Allergic rhinitis: reduces nasal congestion, itching, sneezing and rhinorrhea associated with perennial allergy. Seasonal allergic rhinitis: provides symptom relief during pollen or other seasonal allergen exposure.

Mommox may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasal irritation or burning sensation - Epistaxis (nosebleeds) - Headache - Altered taste or throat irritation

Serious or Rare Side Effects: - Nasal septal perforation - Adrenal suppression with prolonged use - Cataracts or glaucoma - Severe allergic reaction (anaphylaxis) - Opportunistic fungal infection of the nasal cavity

Before using Mommox, consider the following safety measures. - Pregnancy: consult a healthcare professional as safety data are limited. - Breastfeeding: weigh potential benefits against unknown risks. - Pediatric use: safety not established for children under the recommended age. - Concomitant nasal decongestants: avoid simultaneous use to reduce irritation. - Duration of therapy: limit use to the shortest effective period to minimize systemic exposure. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mommox may interact with other medications; monitor as indicated.

Major Interactions (Avoid): - Systemic corticosteroids: increased risk of systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise local drug exposure.

Moderate Interactions (Monitor Closely): - Antihistamines: additive symptom control, monitor for excessive sedation. - Nasal saline irrigations: generally safe, no significant interaction. - Live vaccines: potential reduced efficacy if systemic absorption occurs.